<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04560933</url>
  </required_header>
  <id_info>
    <org_study_id>270-701</org_study_id>
    <nct_id>NCT04560933</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia A</brief_title>
  <acronym>SAAVY</acronym>
  <official_title>A Prospective, Observational Study Evaluating Seroprevalence and Rate of Seroconversion of Antibodies Against Adeno-associated Virus (AAV) Serotypes and Exploratory Vectors in Subjects With Hemophilia A in the United States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To quantify the seroprevalence of antibodies to AAV5, AAV6, and AAV8 and the seroconversion&#xD;
      rate over varying follow-up intervals in subjects with hemophilia A&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, decentralized, patient-centered, prospective, observational study&#xD;
      utilizing biospecimen samples collected from hemophilia A subjects across the United States&#xD;
      to evaluate and characterize seroprevalence and the rate of seroconversion of antibodies&#xD;
      against AAV serotypes and exploratory vectors, and to investigate the associated factors that&#xD;
      may influence the vector titers.&#xD;
&#xD;
      Relevant medical findings will also be collected from the subject, as well as symptoms&#xD;
      related to hemophilia A. The collection of medical history may include major illnesses,&#xD;
      diagnoses, and surgeries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the Seroprevalence of antibodies to AAV vectors in patients with hemophilia A</measure>
    <time_frame>Baseline</time_frame>
    <description>To assess the Seroprevalence of antibodies to AAV vectors in patients with hemophilia A at Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the rate of Seroconversion of antibodies to AAV vectors in patients with hemophilia A</measure>
    <time_frame>Change from baseline through Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe and characterize AAV vector titer values in subjects with Hemophilia A</measure>
    <time_frame>Change from baseline through Week 12</time_frame>
    <description>To describe and characterize AAV vector titer values in subjects with Hemophilia A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe and characterize AAV vector titer values in subjects with Hemophilia A</measure>
    <time_frame>Change from baseline through Week 24</time_frame>
    <description>To describe and characterize AAV vector titer values in subjects with Hemophilia A</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hemophilia A</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample collection</intervention_name>
    <description>Blood sample collection</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects diagnosed with Hemophilia A&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects diagnosed with Hemophilia A&#xD;
&#xD;
          -  Subjects aged 18years or over at time of entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently participating in an interventional study of any investigational product,&#xD;
             device or procedure.&#xD;
&#xD;
          -  Subjects who have been previously treated with AAV vector gene therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Stephen Flach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manil Vaghela, BSc</last_name>
    <phone>+447823336138</phone>
    <email>manil.vaghela@bmrn.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance Inc</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Flach, MD</last_name>
      <phone>608-443-1599</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

